about
Is a multivalent hand, foot, and mouth disease vaccine feasible?Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform.Platelets interact with Coxsackieviruses B and have a critical role in the pathogenesis of virus-induced myocarditis.New perspectives of infections in cardiovascular diseaseElectrophysiological alterations in a murine model of chronic coxsackievirus B3 myocarditisThe impact of juvenile coxsackievirus infection on cardiac progenitor cells and postnatal heart developmentIdentification and typing of human enterovirus: a genomic barcode approachCharacterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines.Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence.Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy.Vaccination procedures against Coxsackievirus-induced heart disease.Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis.Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1.Replication of coxsackievirus B3 in primary cell cultures generates novel viral genome deletionsOver-expression of mitochondrial antiviral signaling protein inhibits coxsackievirus B3 infection by enhancing type-I interferons production.Spontaneous autoimmune myocarditis and cardiomyopathy in HLA-DQ8.NODAbo transgenic mice.Ribosomal Initiation Complex Assembly within the Wild-Strain of Coxsackievirus B3 and Live-Attenuated Sabin3-like IRESes during the Initiation of TranslationMolecular determinants of disease in coxsackievirus B1 murine infection.Altered interactions between stem-loop IV within the 5' noncoding region of coxsackievirus RNA and poly(rC) binding protein 2: effects on IRES-mediated translation and viral infectivity.Viral persistence and chronic immunopathology in the adult central nervous system following Coxsackievirus infection during the neonatal period.Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.Relevance of molecular mimicry in the mediation of infectious myocarditis.Visceral pathology of acute systemic injury in newborn mice on the onset of Coxsackie virus infectionAnalysis of translational initiation in coxsackievirus B3 suggests an alternative explanation for the high frequency of R+4 in the eukaryotic consensus motif.Regulation of the immune response during infectious myocarditis.Viral myocarditis--diagnosis, treatment options, and current controversies.SAR evolution and discovery of benzenesulfonyl matrinanes as a novel class of potential coxsakievirus inhibitors.Total Flavonoids of Astragalus Plays a Cardioprotective Role in Viral Myocarditis.5' terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart.Autophagosome supports coxsackievirus B3 replication in host cells.Functional Consequences of RNA 5'-Terminal Deletions on Coxsackievirus B3 RNA Replication and Ribonucleoprotein Complex Formation.Pathogenesis of coxsackievirus B2 in mice: characterisation of clinical isolates of the coxsackievirus B2 from patients with myocarditis and aseptic meningitis in Korea.MOPS and coxsackievirus B3 stability.The novel asymmetric entry intermediate of a picornavirus captured with nanodiscs.Antiviral effects of interferon-β are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3.A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs.Synthesis and biological evaluation of N-substituted sophocarpinic acid derivatives as coxsackievirus B3 inhibitors.Quantitative genomic and antigenomic enterovirus RNA detection in explanted heart tissue samples from patients with end-stage idiopathic dilated cardiomyopathy.Evaluation of salidroside in vitro and in vivo genotoxicity.
P2860
Q27010349-54D13AB8-5177-4CBB-9B60-9EAD929D52F3Q30586653-4EFD2B87-290D-4F65-8614-E97D5B8022B5Q33418689-5107423D-4932-4D4C-B815-95B9E5AE072BQ33587960-2765C101-3925-44E6-B1BC-7DD54B5A3AB3Q33828989-6EC80EDB-6954-4552-A07C-A3FE16F2F944Q33982587-B768AFE6-ED21-406D-9C65-9984C3076791Q34056244-C2AEF462-28F3-4577-A204-843B14ED0DA9Q34093830-5719DFA9-F994-486F-8666-86C65EE75C69Q34359584-9FEB889B-B74A-43C7-A924-7CC066FC05BAQ35483420-11C6773B-A483-49CE-B9AD-5813B8EED2FAQ35623387-BB9FC6A3-A7BC-42A1-9F78-2A03BD0B8956Q35826103-03A51957-860D-4506-907E-149DF0DF4C54Q36202823-9F196060-C626-4627-84B2-9E6F7A9E92F6Q36483302-43E35C78-5D0B-49AB-9724-6BF2FDF09CAAQ36539027-DDC3EF5B-8815-4152-8227-E5CFEE6ADC8EQ36616874-3FDC88AF-DAB4-4B81-B28C-31A1708C0376Q36790234-548C5E06-6513-4AC5-9ED8-376A73EAFF0FQ36914819-0B1691B2-3788-4D9A-AD71-D21D7CA43C53Q37222173-7FC3ACBB-8463-4A3E-8BC6-18EBA4FBACDCQ37333951-9B5BC829-D064-4E1B-AFE3-F5B8E0930CB8Q37340465-E39E5006-8766-4C31-A2FE-93B3252E542CQ37619855-C3DFA77E-16E3-448D-9D64-D274C5EFDD5BQ37676717-E5D3E5B2-91E2-41E2-BE56-D9F8E4D162DEQ37743932-512D1EC0-F40D-43C9-AAB0-BE7280D9C566Q38180743-8F6C268D-9E0E-4BC0-B951-D098B8CA0A44Q38551013-086851C0-320E-4720-959F-BD20A36B9B32Q38794993-6A691303-9CBC-4564-9EB9-87E127377B24Q39404219-1E39AB6A-2B25-404C-9BC1-20EEC5D6B8E4Q39601052-F0BDFFC8-A806-423D-817E-7D867556B187Q39966085-3642B389-CBC3-4A75-B3C1-76C3AB60457CQ40187551-FD6145D0-C926-40E7-83B8-50DA9AEA2085Q40254630-D1EECF4B-978C-47E5-A147-A715B1BE3A46Q40414573-7B02A7F8-0B51-4F41-97DE-C758EA9FE2BFQ40558572-870AFAF3-6A73-475B-9AF9-18B80573F6E8Q41878792-A5B90378-27E5-4EA7-805E-9BC1CA9D419CQ41897207-5CA074FE-85C6-4AA5-8AC0-D456E61EA67DQ41905518-F3B80600-50F0-4DC0-A8D4-DD7104455C05Q42281820-9682F638-0CA0-40E4-B1E1-8286A09E4986Q42691275-A0653854-EC47-4EA9-BCAC-47D5E5E29DBBQ43122186-313942C7-3F87-4F44-8AEC-F0399F8C0FA5
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The group B coxsackieviruses and myocarditis.
@ast
The group B coxsackieviruses and myocarditis.
@en
The group B coxsackieviruses and myocarditis.
@nl
type
label
The group B coxsackieviruses and myocarditis.
@ast
The group B coxsackieviruses and myocarditis.
@en
The group B coxsackieviruses and myocarditis.
@nl
prefLabel
The group B coxsackieviruses and myocarditis.
@ast
The group B coxsackieviruses and myocarditis.
@en
The group B coxsackieviruses and myocarditis.
@nl
P2093
P2860
P356
P1476
The group B coxsackieviruses and myocarditis.
@en
P2093
P2860
P304
P356
10.1002/RMV.326
P577
2001-11-01T00:00:00Z